Abstract:Breast cancer is the most frequent neoplasm in the world. As for its molecular typing, patients with hormone receptor-positive breast cancer accounted for about 70%. Endocrine therapy (ET) has become an important measure for treatment of breast cancer. However, endocrine resistance and tumor progression occur after exposure to first line ET, with a median time of exposure of 1 year. Metastatic breast cancer is difficult to control, the median overall survival is around 3 years, and the 5-year survival rate is only 25%. Therefore, understanding the mechanism of endocrine resistance is conducive to developing targeted therapies and prolonging the patients’survival rate. In this review, we analyze the main mechanism and research progress of endocrine resistance in breast cancer.
罗锦琳, 欧阳慧婷, 邹联洪, 范培芝. 乳腺癌内分泌耐药机制的研究进展[J]. 实用预防医学, 2022, 29(4): 510-513.
LUO Jin-lin, OUYANG Hui-ting, ZOU Lian-hong, FAN Pei-zhi. Research progress in mechanism of resistance to endocrine therapy in breast cancer. , 2022, 29(4): 510-513.
[1] Szostakowska M, Trebińska-Stryjewska A, Grzybowska EA, et al.Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals[J]. Breast Cancer Res Treat,2019,173(3):489-497. [2] González-Conde M, Yaxez-Gómez C, López-López R, et al. Liquid biopsy: a new tool for overcoming CDKi resistance mechanisms in luminal metastatic breast cancer[J]. J Pers Med,2021,11(5):407. [3] García-Becerra R, Santos N, Díaz L, et al. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance[J]. Int J Mol Sci,2012,14(1):108-145. [4] Sakunrangsit N, Ketchart W. Plumbagin inhibited AKT signaling pathway in HER-2 overexpressed-endocrine resistant breast cancer cells[J].Eur J Pharmacol,2020,868:1728778. [5] Spring LM, Wander SA, Andre F, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future[J]. Lancet,2020,395(10226):817-827. [6] Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and epigenetics strategies to reverse breast cancer[J]. Cells,2019,8(10):1214. [7] Tian Y, Xu H, Farooq AA, et al. Maslinic acid induces autophagy by down-regulating HSPA8 in pancreatic cancer cells[J]. Phytother Res,2018,32(7):1320-1331. [8] Shukla S, Penta D, Mondal P, et al. Epigenetics of breast cancer: clinical status of epi-drugs and phytochemicals[J]. Adv Exp Med Biol,2019,1152:293-310. [9] Patel DJ. A structural perspective on readout of epigenetic histone and DNA methylation marks[J]. Cold Spring Harb Perspect Biol,2016,8(3):a018754. [10] Liu SS, Li Y, Zhang H, et al. The ERalpha-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive breast cancer[J]. Theranostics,2020,10(23):10729-10742. [11] Shi Q, Li Y, Li S, et al. LncRNA DILA1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer[J]. Nat Commun,2020,11(1):5513. [12] Ma T, Liang Y, Li Y, et al. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer[J]. Cell Signal,2020,68:109536. [13] Wang J, Xie S, Yang J, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy[J]. J Hematol Oncol,2019,12(1):81. [14] Han X, Li Q, Liu C, et al. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer[J]. J Cell Biochem,2019,120(8):12966-12976. [15] He M, Jin Q, Chen C,et al.The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells[J]. Oncogene,2019,38(28):5551-5565. [16] Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells[J]. Breast Cancer Res Treat,2014, 147(2):423-431. [17] 李子博, 周江, 周琳, 等. 长链非编码RNA CRNDE检测在乳腺癌诊断中的意义[J]. 实用预防医学,2018,25(3):276-279. [18] Li J, Lu M, Jin J, et al. miR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22[J]. Cell Physiol Biochem,2018,50(1):136-149. [19] Chen MJ,Cheng YM,Chen CC,et al. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM[J]. Biochem Biophys Res Commun,2017,483(2):840-846. [20] Zhu J, Zou Z, Nie P, et al. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression[J]. Cell Death Dis,2016,7(11):e2454. [21] Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial[J]. Lancet Oncol,2019,20(12):1750-1759. [22] Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer[J]. N Engl J Med,2019,381(4):307-316. [23] Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial[J]. JAMA Oncol,2020,6(1):116-124. [24] Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3[J]. J Clin Oncol,2018,36(24):2465-2472. [25] Abdel-Razeq H. Current frontline endocrine treatment options for women with hormone receptor-positive, humam epidermal growth factor receptor 2 (HER2)-negative advanced-stage breast cancer[J]. Hematol Oncol Stem Cell Ther,2019,12(1):1-9. [26] Jansen VM, Bhola NE, Bauer JA, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer[J]. Cancer Res,2017,77(9):2488-2499. [27] Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer[J]. Cancer Res,2016,76(8):2301-2313. [28] Jin X, Ge LP, Li DQ, et al. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2transcriptional activation in ER+ breast cancer[J]. Mol Cancer,2020,19(1):87. [29] Formisano L, Lu Y, Servetto A, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer[J]. Nat Commun,2019,10(1):1373. [30] Li Z, Razavi P, Li Q, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway[J]. Cancer Cell,2018,34(6):893-905. [31] O'Brien NA, McDermott MSJ, Conklin D, et al. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer[J]. Breast Cancer Res,2020,22(1):89. [32] Pandey K, An HJ, Kim SK, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review[J]. Int J Cancer,2019,145(5):1179-1188. [33] Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer[J]. N Engl J Med,2019,380(20):1929-1940. [34] Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis[J]. Lancet Oncol,2019,20(10):1360-1369. [35] Mita MM,Mita AC,Moseley JL,et al. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies[J]. Br J Cancer,2017,117(9):1258-1268. [36] Murphy CG. The role of CDK4/6 inhibitors in breast cancer[J]. Curr Treat Options Oncol,2019,20(6):52. [37] Bardia A, Hurvitz SA, DeMichele A, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR(+)/HER2(-) advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)[J]. Clin Cancer Res,2021,27(15):4177-4185.